Skip to content
The Policy VaultThe Policy Vault

Vanflyta (quizartinib tablets − Daiichi Sankyo) — Cigna

Acute Myeloid Leukemia (AML)

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has FLT3-ITD mutation-positive disease as detected by an approved test

Approval duration

1 year